. Author manuscript; available in PMC: 2011 Apr 22.

Published in final edited form as: J Med Chem. 2010 Apr 22;53(8):3133–3141. doi: 10.1021/jm901782m

Table 1.

Anti-HIV-1 replication activities for BA and MA derivatives in acutely infected MT-2 cell lines^a

Compd	EC₅₀ (μM)	IC₅₀ (μM)	Therapeutic Index
AZT	0.034	1,870	55,000
2	0.0013	42.78	32,907
4	2.2	41.89	19
5	17.3	40.93	2.4
6	NS	41.06	–
7	NS	40.27	–
8	0.18	42.51	236.2
9	0.12	43.83	365.3
10	0.0087	32.78	3,768
11	0.048	41.75	869.8
12	0.0006	36.41	60,683
13	NS	> 10	–
14	NS	> 10	–
16	NS	> 10	–
17	NS	> 10	–
18	NS	> 10	–
19	NS	> 10	–
20	NS	> 10	–
21	NS	> 10	–
33 (9+10)	0.016	44.93	2,808

All data presented are averages of at least two separate experiments performed by Panacos Pharmaceutical Inc. EC₅₀: concentration that inhibits HIV-1 replication by 50%. IC₅₀: concentration that inhibits mock-infected cell growth by 50%. TI = IC₅₀/EC₅₀. NS: no suppression at the testing concentration.